Renaissance Technologies LLC Reduces Position in Qiagen NV (QGEN)
Renaissance Technologies LLC decreased its holdings in shares of Qiagen NV (NASDAQ:QGEN) by 9.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 509,308 shares of the company’s stock after selling 53,400 shares during the quarter. Renaissance Technologies LLC’s holdings in Qiagen were worth $18,417,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in QGEN. Wells Fargo & Company MN raised its stake in Qiagen by 22.2% during the first quarter. Wells Fargo & Company MN now owns 152,446 shares of the company’s stock worth $4,926,000 after acquiring an additional 27,703 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Qiagen by 3.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 214,861 shares of the company’s stock worth $6,943,000 after acquiring an additional 6,868 shares during the period. Toronto Dominion Bank acquired a new stake in Qiagen during the first quarter worth about $473,000. Brinker Capital Inc. acquired a new stake in Qiagen during the first quarter worth about $440,000. Finally, Natixis Advisors L.P. raised its stake in Qiagen by 51.6% during the first quarter. Natixis Advisors L.P. now owns 43,722 shares of the company’s stock worth $1,413,000 after acquiring an additional 14,874 shares during the period. Hedge funds and other institutional investors own 62.23% of the company’s stock.
NASDAQ QGEN opened at $37.44 on Wednesday. Qiagen NV has a 52 week low of $30.20 and a 52 week high of $39.45. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.59 and a current ratio of 5.07.
Several equities research analysts recently weighed in on QGEN shares. Morgan Stanley increased their price objective on shares of Qiagen from $37.00 to $38.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 1st. BidaskClub lowered shares of Qiagen from a “hold” rating to a “sell” rating in a research note on Thursday, September 13th. Commerzbank reiterated a “buy” rating on shares of Qiagen in a research note on Wednesday, August 29th. Jefferies Financial Group reiterated a “neutral” rating on shares of Qiagen in a research note on Wednesday, June 6th. Finally, Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research note on Friday, August 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $38.33.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
See Also: Google Finance
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.